Fennec’s Pedmark is reportedly the only FDA-approved therapy to reduce cisplatin-induced hearing loss in pediatric patients. Fennec Phar maceuticals reported its strongest quarter yet for Pedmark (sodium thiosulfate injection), with second-quarter 2026 net product sales climbing to $17.1 million, up 78% year over year compared to $9.7 million in the same period a year earlier....
Continue reading at Hearing Review
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable clinical change; this is a financial performance report, but audiologists treating pediatric oncology patients should be aware that Pedmark availability is increasing, reinforcing existing referral pathways for cisplatin-treated children.
Record adoption of the only FDA-approved otoprotective agent for pediatric cisplatin patients signals growing integration of hearing-preservation protocols in pediatric oncology, which has downstream implications for audiology referral volume and counseling practices.
- 01Fennec Pharmaceuticals reported 78% year-over-year revenue growth for Pedmark in Q2 2026.
- 02Pedmark (sodium thiosulfate injection) remains the only FDA-approved therapy to reduce cisplatin-induced hearing loss in children.
- 03Record-high net product sales suggest rapidly expanding clinical uptake in pediatric oncology settings.
- 04Growth reflects increasing awareness and adoption of otoprotection protocols among oncology teams.
- 05Higher Pedmark use may lead to increased post-treatment audiology referrals as more children preserve usable hearing.
Pedmark is the only FDA-approved therapy to reduce cisplatin-induced ototoxic hearing loss in pediatric patients.
press releasesupportedFennec Pharmaceuticals reported a 78% revenue increase for Pedmark in Q2 2026, reaching record net product sales.
press releasesupported
